Baseline clinical and functional data
| PAH | Valvular heart disease | |||||
| Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 | |
| Sex | F | F | F | F | F | F |
| Age at diagnosis yrs | 50 | 54 | 51 | 57 | 55 | 62 |
| BMI kg·m−2 | 24.2 | 32 | 41.4 | 49 | 41 | 34 |
| Duration of benfluorex exposure months | 54 | 36 | 3 | 120 | ∼120 | 60 |
| Cumulative dosage g | 246 | 328 | 40 | 1095 | 1642 | 821 |
| Time between start of benfluorex use and symptoms yrs | 4 | 1 | <1 | Several | Several | 5 |
| Time between start of benfluorex use and diagnosis yrs | 4.5 | 3 | 10 | 10 | 11 | 5 |
| Search for known drug related causes | Negative | Negative | Negative | Negative | Positive (dexfenfluramine <3 months several years ago) | Positive (dexfenfluramine <3 months several years ago) |
| NYHA functional class | III | III | III | III | III | III |
PAH: pulmonary arterial hypertension; BMI: body mass index; NYHA: New York Heart Association; F: female.